DexCom, Inc. (NASDAQ:DXCM) Shares Bought by Bank Pictet & Cie Europe AG

Bank Pictet & Cie Europe AG raised its holdings in shares of DexCom, Inc. (NASDAQ:DXCM - Free Report) by 5.9% in the 1st quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 117,575 shares of the medical device company's stock after acquiring an additional 6,512 shares during the quarter. Bank Pictet & Cie Europe AG's holdings in DexCom were worth $8,029,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently made changes to their positions in DXCM. Congress Asset Management Co. increased its position in DexCom by 5,456.9% during the fourth quarter. Congress Asset Management Co. now owns 1,356,941 shares of the medical device company's stock worth $105,529,000 after buying an additional 1,332,522 shares during the last quarter. Proficio Capital Partners LLC acquired a new stake in shares of DexCom in the 4th quarter valued at approximately $5,812,000. SBI Securities Co. Ltd. bought a new stake in shares of DexCom during the fourth quarter worth $49,000. Asset Management One Co. Ltd. increased its stake in shares of DexCom by 3.4% in the fourth quarter. Asset Management One Co. Ltd. now owns 243,375 shares of the medical device company's stock valued at $19,528,000 after buying an additional 7,901 shares during the period. Finally, Van ECK Associates Corp boosted its holdings in DexCom by 325.0% in the fourth quarter. Van ECK Associates Corp now owns 85,813 shares of the medical device company's stock valued at $6,674,000 after acquiring an additional 65,622 shares during the last quarter. 97.75% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at DexCom

In other news, EVP Michael Jon Brown sold 10,000 shares of the firm's stock in a transaction that occurred on Friday, May 23rd. The shares were sold at an average price of $84.28, for a total value of $842,800.00. Following the completion of the transaction, the executive vice president now owns 95,602 shares of the company's stock, valued at approximately $8,057,336.56. This trade represents a 9.47% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, EVP Sadie Stern sold 6,184 shares of the stock in a transaction on Tuesday, May 27th. The shares were sold at an average price of $85.11, for a total value of $526,320.24. Following the completion of the sale, the executive vice president now owns 109,621 shares in the company, valued at approximately $9,329,843.31. The trade was a 5.34% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 0.32% of the company's stock.

Analyst Ratings Changes

DXCM has been the topic of a number of research reports. Canaccord Genuity Group upped their target price on DexCom from $103.00 to $106.00 and gave the stock a "buy" rating in a research report on Friday, May 2nd. Piper Sandler lowered their price target on shares of DexCom from $100.00 to $90.00 and set an "overweight" rating on the stock in a report on Friday, May 2nd. Robert W. Baird dropped their price target on shares of DexCom from $115.00 to $105.00 and set an "outperform" rating on the stock in a research note on Friday, May 2nd. The Goldman Sachs Group started coverage on DexCom in a report on Friday, May 30th. They set a "buy" rating and a $104.00 target price for the company. Finally, Wells Fargo & Company reaffirmed an "overweight" rating on shares of DexCom in a report on Saturday, March 8th. Four equities research analysts have rated the stock with a hold rating, sixteen have issued a buy rating and three have assigned a strong buy rating to the company. According to MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $98.50.

DexCom Stock Performance

Shares of NASDAQ DXCM traded down $1.17 during mid-day trading on Tuesday, hitting $81.83. The stock had a trading volume of 2,685,622 shares, compared to its average volume of 4,343,966. DexCom, Inc. has a twelve month low of $57.52 and a twelve month high of $117.49. The firm has a market cap of $32.09 billion, a PE ratio of 50.30, a PEG ratio of 1.77 and a beta of 1.46. The company has a debt-to-equity ratio of 0.55, a quick ratio of 1.32 and a current ratio of 1.50. The company has a 50 day moving average of $78.95 and a two-hundred day moving average of $79.36.

DexCom (NASDAQ:DXCM - Get Free Report) last posted its earnings results on Thursday, May 1st. The medical device company reported $0.32 EPS for the quarter, missing analysts' consensus estimates of $0.33 by ($0.01). The business had revenue of $1.04 billion for the quarter, compared to analyst estimates of $1.02 billion. DexCom had a net margin of 12.90% and a return on equity of 30.05%. DexCom's revenue was up 12.5% on a year-over-year basis. During the same quarter last year, the business earned $0.32 earnings per share. Research analysts predict that DexCom, Inc. will post 2.03 EPS for the current fiscal year.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.